Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer
Abstract The Zero Childhood Cancer Program is a precision medicine program to benefit
children with poor-outcome, rare, relapsed or refractory cancer. Using tumor and germline …
children with poor-outcome, rare, relapsed or refractory cancer. Using tumor and germline …
Targeting Akt in cancer for precision therapy
H Hua, H Zhang, J Chen, J Wang, J Liu… - Journal of Hematology & …, 2021 - Springer
Biomarkers-guided precision therapeutics has revolutionized the clinical development and
administration of molecular-targeted anticancer agents. Tailored precision cancer therapy …
administration of molecular-targeted anticancer agents. Tailored precision cancer therapy …
[HTML][HTML] Challenges and opportunities for pancreatic cancer immunotherapy
AS Bear, RH Vonderheide, MH O'Hara - Cancer cell, 2020 - cell.com
Pancreatic ductal adenocarcinoma (PDA) is among the most immune-resistant tumor types.
Its unique genomic landscape shaped by oncogenic drivers promotes immune suppression …
Its unique genomic landscape shaped by oncogenic drivers promotes immune suppression …
An organoid platform for ovarian cancer captures intra-and interpatient heterogeneity
O Kopper, CJ De Witte, K Lõhmussaar… - Nature medicine, 2019 - nature.com
Ovarian cancer (OC) is a heterogeneous disease usually diagnosed at a late stage.
Experimental in vitro models that faithfully capture the hallmarks and tumor heterogeneity of …
Experimental in vitro models that faithfully capture the hallmarks and tumor heterogeneity of …
The NCI-MATCH trial: lessons for precision oncology
Abstract The NCI-MATCH (Molecular Analysis for Therapy Choice) trial (NCT02465060) was
launched in 2015 as a genomically driven, signal-seeking precision medicine platform trial …
launched in 2015 as a genomically driven, signal-seeking precision medicine platform trial …
Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA
Public neoantigens (NeoAgs) represent an elite class of shared cancer-specific epitopes
derived from recurrently mutated driver genes. Here we describe a high-throughput platform …
derived from recurrently mutated driver genes. Here we describe a high-throughput platform …
Haplotype-aware analysis of somatic copy number variations from single-cell transcriptomes
Genome instability and aberrant alterations of transcriptional programs both play important
roles in cancer. Single-cell RNA sequencing (scRNA-seq) has the potential to investigate …
roles in cancer. Single-cell RNA sequencing (scRNA-seq) has the potential to investigate …
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
YL Verschoor, J van de Haar, JG van den Berg… - Nature medicine, 2024 - nature.com
Gastric and gastroesophageal junction (G/GEJ) cancers carry a poor prognosis, and despite
recent advancements, most patients die of their disease. Although immune checkpoint …
recent advancements, most patients die of their disease. Although immune checkpoint …
Pan-cancer landscape of homologous recombination deficiency
L Nguyen, J WM Martens, A Van Hoeck… - Nature …, 2020 - nature.com
Homologous recombination deficiency (HRD) results in impaired double strand break repair
and is a frequent driver of tumorigenesis. Here, we develop a genome-wide mutational scar …
and is a frequent driver of tumorigenesis. Here, we develop a genome-wide mutational scar …
Genomic and phenotypic heterogeneity in prostate cancer
From a clinical, morphological and molecular perspective, prostate cancer is a
heterogeneous disease. Primary prostate cancers are often multifocal, having …
heterogeneous disease. Primary prostate cancers are often multifocal, having …